Phase 3 post-hoc analysis indicates less fentanyl and overall illicit opioid use for weekly/monthly buprenorphine depots versus daily standard treatment in a difficult to treat patient population LUND ...
Camurus, a Swedish research-based pharmaceutical company, announced that the European Commission (EC) has approved weekly and monthly Buvidal (prolonged release buprenorphine) for the treatment of ...
LUND, Sweden, March 26, 2021 /PRNewswire/ -- Camurus today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency's (EMA) has issued a positive ...
LUND, Sweden, Nov. 26, 2019 /PRNewswire/ -- Camurus announced today topline results from the 24-week, randomized, controlled, open-label, DEBUT study of weekly and monthly Buvidal® (prolonged-release ...
The EU’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a new dose of Camurus’ prolonged-release injection opioid dependence treatment. Buvidal, which contains ...
LUND, Sweden, Nov. 22, 2018 /PRNewswire/ -- Camurus announced today that the European Commission (EC) has approved weekly and monthly Buvidal® (prolonged release buprenorphine) for the treatment of ...
Camurus, a Swedish, science-led biopharmaceutical company, announced topline results from the 24-week, randomized, controlled, open-label, DEBUT study of weekly and monthly Buvidal (prolonged-release ...
The full CMI on the next page has more details. If you are worried about being given this medicine, speak to your doctor, nurse practitioner or pharmacist. Buvidal contains the active ingredient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results